Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

Vaccine

Volumn 27, Issue 45, 2009, Pages 6284-6290

  Schwarz, Tino F ^a   Horacek, Thomas ^b   Knuf, Markus ^c   Damman, Hanns Gerd ^d   Roman, François ^e   Dramé, Mamadou ^e   Gillard, Paul ^e   Jilg, Wolfgang ^f  

^a Stiftung Juliusspital   (Germany)

^b Medical Practice Witten ^*  (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d Clinical Research Institute Schwerin   (Germany)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adjuvant; H5N1; Pre pandemic vaccination

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VACCINE IBCDC RG2; INFLUENZA VACCINE NIBRG 14; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; FEMALE; GERMANY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INDONESIA; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; MALE; MULTICENTER STUDY; NORMAL HUMAN; PANDEMIC; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRAIN IDENTIFICATION; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VIET NAM;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CROSS PROTECTION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 70350025172     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.040     Document Type: Article

References (30)

1. World Health Organization (WHO). Avian influenza. http://www.who.int/csr/disease/avian_influenza/index.html; [accessed November 18, 2008].
2. Peiris M.J.S., de Jong M.D., and Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20 (2007) 243-267
3. Gambotto A., Barratt-Boyes S.M., de Jong M.D., Neumann G., and Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 371 (2008) 1464-1475
4. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 2008;358:261-73.
5. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products, April 5, 2004.
6. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
7. US Food and Drug Administration. Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. http://www.fda.gov/cber/gdlns/panfluvac.htm; [accessed November 18, 2008].
8. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to use of reverse genetics for rapid development of influenza vaccines. Lancet 363 (2004) 1009-1013
9. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. September 2008. http://www.who.int/csr/disease/avian_influenza/guidelines/h5n1virus/en/i ndex.htlm; [accessed November 18, 2008].
10. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1345-1351
11. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997
12. Ehrlich H.J., Müller M., Oh H.M.L., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 (2008) 2573-2584
13. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet 370 (2007) 580-589
14. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 (2008) 667-675
15. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., and Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3 2 (2008) e1665 doi:10.1371/journal.pone.0001665
16. Rumke H.C., Bayas J.M., de Juanes J.M., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26 (2008) 2378-2388
17. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H.M., et al. Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PloS One 3 1 (2008) e1401 doi:10.1371/journal.pone.0001401
18. Hehme N., Engelmann H., Kuenzel W., Neumeier E., and Sänger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res. 103 (2004) 163-171
19. Kendal A.P., Pereira M.S., and Skehel J.J. Hemagglutination inhibition. In: Kendal A.P., Pereira M.S., and Skehel J.J. (Eds). Concepts and procedures for laboratory-based influenza surveillance (1982), Centers for Disease Control and Prevention and Pan-American Health Organization, Atlanta B17-E35
20. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
21. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 (2004) 91-95
22. Germann T.C., Kadau K., Longini Jr. I.M., and Macken C.A. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 103 (2006) 5935-5940
23. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., and Burke D.S. Strategies for mitigating an influenza pandemic. Nature 442 (2006) 448-452
24. Osterhaus A. Pre- or post-pandemic influenza vaccine? Editorial. Vaccine 25 (2007) 4983-4984
25. El Sahly H.M., and Keitel W.A. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines 7 (2008) 241-247
26. Jennings L.C., Monto A.S., Chan P.K.S., Szucs T.D., and Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8 (2008) 650-658
27. Stephenson I., Nicholson K., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 (2003) 1687-1693
28. Stephenson I., Nicholson K., Hoschler K., Zambon M., Hancock K., De Vos J., et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 395 15 (2008) 1631-1633
29. Goji N., Nolan C., Hill H., Wolff M., Rowe T., and Treanor J. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Final program and abstracts of the 44th Annual Meeting of IDSA. Toronto, October 12-15, 2006:64 (2006) [abstract]
30. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., and Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197 (2008) 580-583